WO2019139360A1 - Nanovésicules issues de faecalibacterium prausnitzii et utilisations associées - Google Patents
Nanovésicules issues de faecalibacterium prausnitzii et utilisations associées Download PDFInfo
- Publication number
- WO2019139360A1 WO2019139360A1 PCT/KR2019/000368 KR2019000368W WO2019139360A1 WO 2019139360 A1 WO2019139360 A1 WO 2019139360A1 KR 2019000368 W KR2019000368 W KR 2019000368W WO 2019139360 A1 WO2019139360 A1 WO 2019139360A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- vesicles
- disease
- parkinson
- myocardial infarction
- Prior art date
Links
- 241000605980 Faecalibacterium prausnitzii Species 0.000 title claims abstract 5
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 42
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 42
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 42
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 42
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 41
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 41
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 40
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 40
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 40
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 40
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 39
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 39
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 39
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 39
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 39
- 201000007270 liver cancer Diseases 0.000 claims abstract description 39
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 39
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 39
- 206010003658 Atrial Fibrillation Diseases 0.000 claims abstract description 38
- 208000006990 cholangiocarcinoma Diseases 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims description 69
- 239000008280 blood Substances 0.000 claims description 69
- 208000029742 colonic neoplasm Diseases 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 210000002700 urine Anatomy 0.000 claims description 15
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 9
- 210000003608 fece Anatomy 0.000 claims description 9
- 206010004593 Bile duct cancer Diseases 0.000 claims description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 7
- 229960005489 paracetamol Drugs 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 238000004445 quantitative analysis Methods 0.000 claims description 5
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims 7
- 241001608234 Faecalibacterium Species 0.000 claims 6
- 244000052616 bacterial pathogen Species 0.000 abstract description 20
- 239000000203 mixture Substances 0.000 abstract description 18
- 230000028327 secretion Effects 0.000 abstract description 17
- 230000002757 inflammatory effect Effects 0.000 abstract description 10
- 230000001717 pathogenic effect Effects 0.000 abstract description 8
- 210000001072 colon Anatomy 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 43
- 238000004458 analytical method Methods 0.000 description 34
- 230000001580 bacterial effect Effects 0.000 description 29
- 238000009826 distribution Methods 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 12
- 238000000692 Student's t-test Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 238000012353 t test Methods 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 206010073069 Hepatic cancer Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 206010061592 cardiac fibrillation Diseases 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000002600 fibrillogenic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 230000030429 T-helper 17 type immune response Effects 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Definitions
- the present invention relates to a nano-vesicle derived from a pathogenic bacterium, such as a gastric cancer, a colon cancer, a liver cancer, a pancreatic cancer, a cholangiocarcinoma, an ovarian cancer, , A bladder cancer, a lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease, and a composition for preventing, improving or treating the disease including the vesicle.
- a pathogenic bacterium such as a gastric cancer, a colon cancer, a liver cancer, a pancreatic cancer, a cholangiocarcinoma, an ovarian cancer, , A bladder cancer, a lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease, and a composition for preventing, improving or treating the disease including the vesicle.
- microbiota or microbiome refers to a microbial community, including true bacteria, archaea, and eukarya in a given settlement.
- the mucous membrane forms a physical barrier that can not pass through particles of 200 nanometers (nm) or larger, and can not pass through the mucous membrane when the bacteria are symbiotic to the mucous membrane.
- the bacterial-derived vesicles are less than 100 nanometers in size, It passes through epithelial cells through the mucosa and is absorbed by our body.
- the locally secreted bacterial-derived vesicles are absorbed through the epithelial cells of the mucosa to induce a local inflammatory reaction.
- the vesicles passing through the epithelium are systemically absorbed through the lymphatic vessels and distributed to each organ, It regulates immune and inflammatory responses.
- vesicles originating from pathogenic Gram-negative bacteria such as E. coli ( Eshcherichia coli ) cause colitis locally, and when they are absorbed into the blood vessels, the vascular endothelial cell inflammatory response causes systemic inflammation, stool, And is also absorbed by insulin-acting muscle cells and the like, leading to insulin resistance and diabetes.
- beneficial bacteria-derived vesicles can control disease by controlling immune function and metabolic dysfunction caused by pathogenic vesicles.
- the immune response to bacterial-derived factors such as vesicles is a Th17 immune response characterized by interleukin (IL) -17 cytokine secretion, which upon exposure to bacterial-derived vesicles secretes IL-6, Induce an immune response.
- IL interleukin
- Tumor necrosis factor-alpha (TNF- ⁇ ) which is secreted by inflammatory cells such as neutrophils and macrophages during the inflammatory process, is characterized by neutrophil infiltration by Th17 immune response It plays an important role in inflammation and cancer development.
- the present invention provides a method of treating a clinical sample of gastric cancer, colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease in comparison with a normal human parvovirus- And it is confirmed that the disease can be diagnosed.
- the vesicles were isolated from the pathogenic bacterium, and the characteristics thereof were analyzed.
- the present inventors have intensively studied to solve the above-mentioned conventional problems.
- the present inventors have found that gastric cancer, colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, And that the content of paracetamycinum purosunicus-derived vesicles in the samples derived from patients with Parkinson's disease was significantly reduced.
- the vesicles were isolated from the cells of the pathogenic bacterium, the inhibition of IL-6 and TNF-alpha secretion by the pathogenic vesicles was remarkably suppressed. Based on this, the present invention was completed .
- the present invention also relates to a pharmaceutical composition for treating gastric cancer, colon cancer, hepatic cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease comprising a parasite derived from a pathogenic bacterium, , Or a composition for preventing, ameliorating, or treating one or more diseases selected from the group consisting of:
- the present invention provides a method of treating gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, Provides a method of providing information for diagnosis:
- the present invention also provides a diagnostic method for gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, biliary cancer, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, or Parkinson's disease comprising the steps of:
- the sample in step (a) may be feces, blood, or urine.
- the primer pair in step (b) may be a primer of SEQ ID NO: 1 or SEQ ID NO: 2.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising gastric cancer, colon cancer, hepatic cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease, which comprises a vesicle derived from a pathogenic bacterium
- the present invention provides a pharmaceutical composition for preventing or treating at least one disease selected from the group consisting of:
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising gastric cancer, colon cancer, hepatic cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease, which comprises a vesicle derived from a pathogenic bacterium, At least one disease prevention or improvement food composition selected from the group consisting of:
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutical composition comprising an effective amount of a bacterium belonging to the genus Acanthopanax senticosus as an active ingredient, , Myocardial infarction, atrial fibrillation, and Parkinson ' s disease.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound selected from the group consisting of gastric cancer, colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation and Parkinson's disease It provides a preventive or therapeutic use of the disease.
- the vesicles may have an average diameter of 10 to 200 nm.
- the vesicle may be naturally or artificially secreted from the pathogenic bacterium.
- the present inventors confirmed that intestinal bacteria are not absorbed into the body but they are absorbed into the body through epithelial cells in the case of bacterial-derived vesicles, and are excreted through the kidneys, liver, and lungs by systemic distribution.
- Stomach cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease by analysis of a bacterial-derived vesicle metagenome present in blood, urine or blood It was confirmed that the vesicles derived from the pathogenic bacterium Pausus nichia in the urine were significantly decreased compared to the normal subjects.
- the present invention provides a method for diagnosing gastric cancer, colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease, and It is anticipated that it may be usefully used in a composition for preventing, ameliorating or treating a food or a drug for the above diseases.
- FIG. 1A is a photograph of the distribution pattern of bacteria and vesicles by time after oral administration of bacteria and bacterial-derived vesicles (EV) to a mouse.
- FIG. 1B is a photograph of blood, kidney , Liver and various organs were extracted to evaluate the distribution patterns of bacteria and vesicles in the body.
- FIG. 2 shows the results of a comparison of the distribution of vesicles derived from Pataribacterium fruticus Niichus after the analysis of the bacterial-derived vesicle metagenomes present in gastric cancer patients and normal human blood.
- FIG. 3 shows the results of a comparison of the distribution of vesicles derived from Pataribacterium furosinii after the analysis of bacterial-derived vesicle metagenomes existing in colon cancer patients and normal feces.
- FIG. 4 shows the results of a comparison of the distribution of vesicles derived from Pataribacterium fruticus Niichus after the analysis of bacterial-derived vesicle metagenomes existing in patients with liver cancer and normal human blood.
- FIG. 5 shows the results of a comparison of the distribution of vesicles derived from Pataribacterium furosinii after the analysis of bacterial-derived vesicle metagenomes existing in pancreatic cancer patients and normal human blood.
- Fig. 6 shows the results of a comparison of the distribution of vesicles derived from Pataribacterium furosinii after the analysis of bacterial-derived vesicle metagenomes existing in patients with biliary cancer and normal human blood.
- Fig. 7 shows the results of a comparison of the distribution of vesicles derived from Pataribacterium furosinii after the analysis of bacterial-derived vesicle metagenomes existing in ovarian cancer patients and normal human blood.
- FIG. 8 shows the results of a comparison of the distribution of vesicles derived from Pataribacterium frutosa Niichi after the analysis of the vesicle-derived vesicle metagenomes in bladder cancer patients and normal blood.
- FIG. 9 shows the results of a comparison of the distribution of vesicles derived from Pataribacterium furosinii after the analysis of bacterial-derived vesicle metagenomes existing in lymphoma patients and normal blood.
- Fig. 10 shows the results of a comparison of the distribution of vesicles derived from the pathogenic bacterium pneumoniae after the analysis of the bacterial-derived vesicle metagenomes present in the myocardial infarction patients and the normal blood.
- Fig. 11 shows the results of a comparison of the distribution of vesicles derived from Pataribacterium furosinii after the analysis of the bacterial-derived vesicle metagenomes present in the atrial fibrillation and normal human blood.
- Fig. 12 shows the results of a comparison of the distribution of vesicles derived from the pathogenic bacterium pneumoniae after the analysis of the bacterial-derived vesicle metagenomes present in Parkinson's disease patients and normal human urine.
- FIGS. 13A and 13B are graphs showing the effect of various concentrations of the paracetamol-derived microbial cells from Macallium bacterium on the macrophage to evaluate the inflammatory mediator effect of the paracase derived from the pathogenic bacterium Escherichia coli As a result of comparison with the case of treatment with E. coli EV, Fig. 13A compares IL-6 secretion and Fig. 13B compares the secretion of TNF-a.
- FIG. 14A and 14B are graphs showing the results of pretreatment of the paracase derived from the pathogenic bacterium E. coli EV prior to the treatment with the E. coli EV to evaluate the antiinflammatory and immunomodulatory effects of the paracase from the pathogenic bacterium, As a result of evaluating the effect on the inflammatory mediator secretion by E. coli vesicle, FIG. 14A compares IL-6 secretion and FIG. 14B compares the secretion of TNF- ⁇ .
- the present invention relates to vesicles derived from Lactobacillus brevis and their uses.
- the present inventors have conducted metagenomic analysis to determine whether a sample derived from Pataribacterium frutosa Niichia can be obtained from samples derived from gastric cancer, colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, It was confirmed that the content of vesicles was significantly reduced, and thus the present invention was completed based on this finding.
- the present invention provides a method for providing information for diagnosis of gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, or Parkinson's disease comprising the following steps:
- diagnosis means, in a broad sense, judging the actual condition of a patient in all aspects. The contents of the judgment are the pathology, etiology, pathology, severity, details of the disease, presence of complications, and prognosis.
- the diagnosis in the present invention is to judge whether or not the disease such as gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and / or Parkinson's disease,
- Nanovesicle or "Vesicle” as used in the present invention means a structure composed of nano-sized membranes secreted from various bacteria.
- Gram-negative bacteria-derived vesicles or outer membrane vesicles have not only lipopolysaccharides but also toxic proteins and bacterial DNA and RNA, and gram-positive bacteria-derived vesicles Has peptidoglycan and lipoteichoic acid which are cell wall components of bacteria as well as protein and nucleic acid.
- nano-vesicles or vesicles are naturally secreted or artificially produced in the pathogenic bacterium, and have a spherical shape and an average diameter of 10 to 200 nm.
- " metagenome "
- metagenome " is also referred to as 'whole milk', and refers to the total of genomes including all viruses, bacteria, fungi, etc. in isolated regions such as soil and animal fields. It is used as a concept of a genome to explain the identification of many microorganisms at once by using a sequencer to analyze microorganisms.
- a metagenome is not a genome or a genome, but a kind of mixed genome as a genome of all species of an environmental unit. This is a term derived from the viewpoint that when defining a species in the course of omics biology development, it functions not only as an existing species but also as a species that interacts with various species to form a complete species.
- it is the subject of techniques that analyze all DNA and RNA regardless of species, identify all species in an environment, identify interactions, and metabolism using rapid sequencing.
- the patient-derived sample may be feces, blood, or urine, but is not limited thereto.
- the present invention provides a pharmaceutical composition for preventing or treating gastric cancer, colon cancer, hepatic cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, And Parkinson's disease.
- the present invention also provides a pharmaceutical composition for preventing or treating at least one disease selected from the group consisting of Parkinson's disease and Parkinson's disease.
- the present invention provides a pharmaceutical composition for treating gastric cancer, colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation , And Parkinson ' s disease.
- prevention used in the present invention refers to the administration of a food or drug composition according to the present invention to treat gastric cancer, colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and / Parkinson 's disease, etc.
- treatment refers to the treatment of gastric cancer, colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and / Parkinson 's disease, etc.
- improvement means all actions that at least reduce the degree of symptom associated with the condition being treated.
- the vesicles can be obtained by culturing a culture solution containing a pathogenic bacterium belonging to the genus Saccharomyces cerevisiae by centrifugation, ultrafast centrifugation, high pressure treatment, extrusion, ultrasonic degradation, cell lysis, homogenization, freezing-thawing, electroporation, Separation by using one or more methods selected from the group consisting of filtration, gel filtration chromatography, pre-flow electrophoresis, and capillary electrophoresis. Further, it may further include processes such as washing for removal of impurities and concentration of the resulting vesicles.
- bacterial and bacterial-derived vesicles were orally administered to mice to evaluate the absorption, distribution, and excretion of bacteria and vesicles in the body.
- the vesicles were not absorbed through the intestinal membrane, Were absorbed and distributed systemically and excreted through the kidneys and liver (see Example 1).
- the stool, blood, or blood of a normal person who matched age and sex in gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, Bacterial metagenomic analysis was carried out using vesicles isolated from urine.
- a clinical sample of patients with gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease See Examples 3 to 13).
- vesicles secreted from the cultured Paciarum bacterium were able to demonstrate immunomodulatory and anti-inflammatory effects.
- the vesicles derived from the various strains of P. falcus nichia After treatment with phagocytes, E. coli-derived vesicles, which are the causative factors of inflammatory diseases, were treated to evaluate inflammatory mediator secretion.
- IL-6 and TNF-a secretion by E. coli-derived vesicles was effectively suppressed by the parasites derived from Parka bacteria (See Example 15).
- the pharmaceutical composition according to the present invention may comprise a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carriers are those conventionally used in the formulation and include, but are not limited to, saline, sterilized water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, And may further contain other conventional additives such as antioxidants and buffers as needed.
- it may be formulated into injectable formulations, pills, capsules, granules, or tablets such as aqueous solutions, suspensions, emulsions and the like by additionally adding diluents, dispersants, surfactants, binders, lubricants and the like.
- Suitable pharmaceutically acceptable carriers and formulations can be suitably formulated according to the respective ingredients using the methods disclosed in Remington's reference.
- the pharmaceutical composition of the present invention is not particularly limited to a formulation, but may be formulated into an injection, an inhalant, an external preparation for skin, or an oral ingestion agent.
- the pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intravenous, subcutaneous, skin, nasal, or airway) according to the desired method, The type of administration, the route of administration, and the time, but may be suitably selected by those skilled in the art.
- a pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type of disease, severity, activity of the drug, The time of administration, the route of administration and the rate of excretion, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts.
- the composition according to the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
- the effective amount of the pharmaceutical composition according to the present invention may vary depending on the age, sex, and body weight of the patient. Generally, 0.001 to 150 mg, preferably 0.01 to 100 mg per 1 kg of body weight is administered daily or every other day Or one to three times a day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.
- the food composition of the present invention comprises a health functional food composition.
- the food composition according to the present invention can be used as it is or in combination with other food or food ingredients, and can be suitably used according to conventional methods.
- the amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement).
- the composition of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material, in the production of food or beverage.
- the amount may be less than the above range.
- the food composition of the present invention has no particular limitation on the ingredients other than those containing the active ingredient as an essential ingredient in the indicated ratios and may contain various flavors or natural carbohydrates as additional ingredients such as ordinary drinks.
- natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol.
- Natural flavors tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above .
- the ratio of the above-mentioned natural carbohydrate can be appropriately determined by a person skilled in the art.
- the food composition of the present invention can be used as a flavoring agent such as a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, Salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. These components may be used independently or in combination. The ratios of these additives can also be appropriately selected by those skilled in the art.
- Example 1 Analysis of intestinal absorption, distribution, and excretion of intestinal bacteria and bacterial-derived vesicles
- Example 2 Analysis of bacterial-derived vesicle metagenomes in clinical samples
- the DNA extracted by the above method was amplified using the above 16S rDNA primer, followed by sequencing (Illumina MiSeq sequencer), outputting the result as a Standard Flowgram Format (SFF) file, and using GS FLX software (v2.9)
- SFF Standard Flowgram Format
- GS FLX software v2.9
- the SFF file was converted into a sequence file (.fasta) and a nucleotide quality score file to confirm the creditworthiness of the lead and to remove the portion with a window (20 bps) average base call accuracy less than 99% (Phred score ⁇ 20) .
- OTU Operational Taxonomy Unit
- clustering is performed according to sequence similarity using UCLUST and USEARCH.
- the genus is 94%
- the family is 90%
- the order is 85% class, 80%
- phylum are clustering based on 75% sequence similarity, and the phylum, class, order, family, genus level
- the bacteria were profiled (QIIME) with a sequence similarity greater than 97% at the genus level using BLASTN and GreenGenes 16S RNA sequence database (108,453 sequence).
- Example 4 Analysis of vesicle meta-genomes from feces bacteria of colon cancer patients
- Example 5 Analysis of vesicle meta-genome derived from blood germ in patients with liver cancer
- Genomic DNA was extracted from the vesicles present in the blood of 331 normal persons whose age and gender matched 86 liver cancer patients by the method of Example 2, and the results were analyzed by metagenomic analysis. The distribution of vesicles was evaluated. As a result, it was confirmed that the vesicles derived from Pataribacterium frutosa Nichia were significantly reduced in the blood of the liver cancer patients compared to the normal blood (see Table 4 and Fig. 4).
- Example 6 Analysis of vesicle meta-genome from blood microbes in pancreatic cancer patients
- Example 8 Analysis of vesicle meta-genome derived from blood bacterium of ovarian cancer patient
- Example 9 Analysis of vesicle meta-genome from blood microbes of bladder cancer patients
- a total of 176 blastomeric blood samples were collected from 91 bladder cancer patients and normal 176 blood samples from patients with bladder cancer.
- the genes were extracted from the vesicles present in the blood and analyzed by metagenomic analysis. The distribution of vesicles was evaluated. As a result, it was confirmed that the vesicles derived from Pataribacterium flaus Nichia were significantly reduced in the blood of the bladder cancer patients compared to the normal blood (see Table 8 and Fig. 8).
- Example 10 Analysis of vesicle metagenomes derived from urine bacteria from patients with lymphoma
- the gene was extracted from the vesicles present in the blood of 53 normal persons who matched the age and sex of 63 lymphoma patients according to the method of Example 2, and the distribution of the vesicles derived from the pathogenic bacterium Pausus nichia was evaluated Respectively. As a result, it was confirmed that vesicles derived from L. pneumoniae were significantly reduced in the blood of lymphoma patients compared with normal blood (see Table 9 and Fig. 9).
- Example 11 Analysis of vesicle-derived vesicle meta-genome from myocardial infarction patients
- Example 12 Analysis of vesicle meta-genomes from blood microbes in patients with atrial fibrillation
- Example 13 Analysis of vesicle metagenomes from urine bacteria of Parkinson's disease patients
- Example 14 Separation of follicles derived from Lactobacillus brevis and induction of inflammation
- Saccharomyces cerevisiae strains were subcultured in a BHI (brain heart infusion) medium until the absorbance (OD600) became 1.0 to 1.5 in an anaerobic chamber at 37 ° C.
- the culture supernatant which did not contain the strain, was recovered and centrifuged at 10,000 g for 15 minutes at 4 ° C, filtered through a 0.45 ⁇ m filter, and the supernatant was applied to a 100 kDa hollow filter membrane using a QuixStand benchtop system (GE Healthcare, UK) And concentrated to a volume of 200 ml through ultrafiltration.
- the resulting supernatant was filtered once again with a 0.22 ⁇ m filter, and the filtered supernatant was centrifuged at 150,000 g at 4 ° C. for 3 hours.
- the pellet was then suspended in Dulbecco's Phosphate Buffered Saline (DPBS). Density gradient centrifugation was then performed with 10%, 40%, and 50% OptiPrep solutions (Axis-Shield PoC AS, Norway) and the OptiPrep solution was diluted with HEPES-buffered saline (20 mM HEPES , 150 mM NaCl, pH 7.4).
- Raw 264.7 cells a mouse macrophage cell line, were infected with various concentrations (0.1, 1, 10 Mu] g / ml), and the secretion amount of the inflammatory mediator (IL-6, TNF- [alpha]) was measured. More specifically, Raw 264.7 cells were plated at 1 ⁇ 10 5 in 24-well cell culture plates and cultured in DMEM (Dulbeco's Modified Eagle's Medium) complete medium for 24 hours. The culture supernatant was collected in a 1.5 ml tube and centrifuged at 3000 g for 5 minutes. The supernatant was collected and stored at 4 ° C for ELISA analysis.
- DMEM Dulbeco's Modified Eagle's Medium
- the mouse macrophage cell line Raw 264.7 cells, E. coli- derived vesicles were treated with various concentrations (0.1, 1, 10 ⁇ ⁇ / ml) and E. coli EV) to measure the secretion of inflammatory mediators (IL-6, TNF- ⁇ ). More specifically, Raw 264.7 cells were plated on 24-well cell culture plates at 1 ⁇ 10 5 cells and then cultured in DMEM complete medium for 24 hours. The culture supernatant was collected in a 1.5 ml tube and centrifuged at 3000 g for 5 minutes. The supernatant was collected and stored at 4 ° C for ELISA analysis.
- Raw 264.7 cells were plated on 24-well cell culture plates at 1 ⁇ 10 5 cells and then cultured in DMEM complete medium for 24 hours. The culture supernatant was collected in a 1.5 ml tube and centrifuged at 3000 g for 5 minutes. The supernatant was collected and stored at 4 ° C for ELISA analysis.
- the parasite derived from the pathogenic bacterium of the present invention is useful as a diagnostic method for gastric cancer, colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation or Parkinson's disease, It can be used as a composition for prevention, improvement or treatment of food or medicines in Korea, so that it is expected to be useful for the related pharmaceutical industry and food industry.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des vésicules issues de Faecalibacterium prausnitzii et des utilisations associées. Il a été confirmé expérimentalement par les présents inventeurs que la proportion des vésicules a été significativement réduite dans des échantillons cliniques provenant de patients atteints d'un cancer gastrique, d'un cancer colorectal, d'un cancer du foie, d'un cancer du pancréas, d'un cholangiocarcinome, d'un cancer de l'ovaire, d'un cancer de la vessie, d'un lymphome, d'un infarctus du myocarde, d'une fibrillation auriculaire, et de la maladie de Parkinson par comparaison avec une personne normale et que les vésicules, après administration, une fois séparées de la souche, inhibent significativement la sécrétion de médiateurs inflammatoires provoquée par des vésicules pathogènes, telles que des vésicules issues de bacilles du côlon. Les vésicules issues de Faecalibacterium prausnitzii selon la présente invention sont censées être utilisées de manière avantageuse dans le but de développer une méthode de diagnostic du cancer gastrique, du cancer colorectal, du cancer du foie, du cancer du pancréas, du cholangiocarcinome, du cancer de l'ovaire, du cancer de la vessie, du lymphome, de l'infarctus du myocarde, de la fibrillation auriculaire et/ou de la maladie de Parkinson, et une composition pour prévenir, soulager ou traiter lesdites maladies.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980007976.2A CN111587295A (zh) | 2018-01-12 | 2019-01-10 | 来源于普氏粪杆菌的纳米囊泡及其用途 |
JP2020538572A JP2021510300A (ja) | 2018-01-12 | 2019-01-10 | フィーカリバクテリウム・プラウスニッツィイ由来のナノ小胞およびその用途 |
EP19738195.7A EP3739068A4 (fr) | 2018-01-12 | 2019-01-10 | Nanovésicules issues de faecalibacterium prausnitzii et utilisations associées |
US15/733,371 US11666607B2 (en) | 2018-01-12 | 2019-01-10 | Nanovesicles derived from Faecalibacterium prausnitzii and uses thereof |
JP2021164124A JP7191411B2 (ja) | 2018-01-12 | 2021-10-05 | フィーカリバクテリウム・プラウスニッツィイ由来のナノ小胞およびその用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180004604 | 2018-01-12 | ||
KR10-2018-0004604 | 2018-01-12 | ||
KR10-2019-0002607 | 2019-01-09 | ||
KR1020190002607A KR102282490B1 (ko) | 2018-01-12 | 2019-01-09 | 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019139360A1 true WO2019139360A1 (fr) | 2019-07-18 |
Family
ID=67218313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/000368 WO2019139360A1 (fr) | 2018-01-12 | 2019-01-10 | Nanovésicules issues de faecalibacterium prausnitzii et utilisations associées |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019139360A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115942944A (zh) * | 2020-06-11 | 2023-04-07 | 伊夫罗生物科学公司 | 使用颤螺旋菌科微生物胞外囊泡治疗疾病和障碍的组合物和方法 |
WO2025011240A1 (fr) * | 2023-07-13 | 2025-01-16 | 慕恩(广州)生物科技有限公司 | Composition pharmaceutique et utilisation associée |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014102009A1 (fr) * | 2012-12-26 | 2014-07-03 | Institut National De La Recherche Agronomique (Inra) | Peptides anti-inflammatoires |
KR20150134356A (ko) * | 2013-03-05 | 2015-12-01 | 리엑스유니버시테이트 그로닝겐 | 염증을 억제하기 위한 페칼리 박테리움 프라우스니치이 htf-f (dsm 26943)의 용도 |
WO2016133324A1 (fr) * | 2015-02-17 | 2016-08-25 | 이화여자대학교 산학협력단 | Procédé pour le diagnostic de maladies respiratoires inflammatoires à l'aide de vésicules de membrane externe dérivés de bactéries |
-
2019
- 2019-01-10 WO PCT/KR2019/000368 patent/WO2019139360A1/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014102009A1 (fr) * | 2012-12-26 | 2014-07-03 | Institut National De La Recherche Agronomique (Inra) | Peptides anti-inflammatoires |
KR20150134356A (ko) * | 2013-03-05 | 2015-12-01 | 리엑스유니버시테이트 그로닝겐 | 염증을 억제하기 위한 페칼리 박테리움 프라우스니치이 htf-f (dsm 26943)의 용도 |
WO2016133324A1 (fr) * | 2015-02-17 | 2016-08-25 | 이화여자대학교 산학협력단 | Procédé pour le diagnostic de maladies respiratoires inflammatoires à l'aide de vésicules de membrane externe dérivés de bactéries |
Non-Patent Citations (3)
Title |
---|
JAFARI, B. ET AL.: "Isolation and characterization of Faecalibacterium prausnitzii extracellular vesicles", VACCINE RESEARCH, vol. 4, no. 3, November 2017 (2017-11-01), pages 51 - 54, XP055625110 * |
LOPEZ-SILES, M. ET AL.: "Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer", INFLAMM. BOWEL. DIS., vol. 22, no. 1, January 2016 (2016-01-01), pages 28 - 41, XP055319233, DOI: 10.1097/MIB.0000000000000590 * |
See also references of EP3739068A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115942944A (zh) * | 2020-06-11 | 2023-04-07 | 伊夫罗生物科学公司 | 使用颤螺旋菌科微生物胞外囊泡治疗疾病和障碍的组合物和方法 |
WO2025011240A1 (fr) * | 2023-07-13 | 2025-01-16 | 慕恩(广州)生物科技有限公司 | Composition pharmaceutique et utilisation associée |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102087105B1 (ko) | 큐프리아비더스 속 세균 유래 나노소포 및 이의 용도 | |
KR20190086382A (ko) | 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도 | |
WO2018030732A1 (fr) | Nanovésicules dérivées de bactéries du genre bacillus et leur utilisation | |
KR102250596B1 (ko) | 비피도박테리움 속 세균 유래 나노소포 및 이의 용도 | |
WO2019139360A1 (fr) | Nanovésicules issues de faecalibacterium prausnitzii et utilisations associées | |
WO2019172598A1 (fr) | Nanovésicules dérivées de bactéries lactobacillus sp., et leur utilisation | |
KR102122903B1 (ko) | 블라우티아 속 세균 유래 나노소포 및 이의 용도 | |
KR102118996B1 (ko) | 베일로넬라 속 세균 유래 나노소포 및 이의 용도 | |
WO2019156449A1 (fr) | Nanovésicules dérivées de bactéries du genre lactococcus et leur utilisation | |
WO2019164197A1 (fr) | Nano-vésicules dérivées de bactéries catenibacterium et utilisation associée | |
KR102118989B1 (ko) | 엔히드로박터 세균 유래 나노소포 및 이의 용도 | |
WO2019172600A1 (fr) | Nanovésicules issues de bactéries enhydrobacter, et leur utilisation | |
WO2019172604A1 (fr) | Nanovésicules issues de bactéries collinsella sp., et leur utilisation | |
WO2019168327A1 (fr) | Nanovésicules issues de bactéries micrococcus et leur utilisation | |
WO2019168328A1 (fr) | Nanovésicules dérivées de bactéries rhizobium sp., et leur utilisation | |
WO2019172597A1 (fr) | Nanovésicules dérivées de bactéries methylobacterium sp. et leur utilisation | |
WO2019164283A1 (fr) | Nano-vésicules dérivées de bactéries de l'espèce blautia et utilisation associée | |
WO2019151825A1 (fr) | Nanovésicules issues de bactéries bifidobacterium, et leur utilisation | |
KR102122894B1 (ko) | 엑시구오박테리움 속 세균 유래 나노소포 및 이의 용도 | |
KR102118198B1 (ko) | 리조비움 속 세균 유래 나노소포 및 이의 용도 | |
KR102118201B1 (ko) | 메틸로박테리움 속 세균 유래 나노소포 및 이의 용도 | |
WO2019168331A1 (fr) | Nanovésicules issues de bactéries pseudomonas, et leur utilisation | |
KR102118993B1 (ko) | 프레보텔라 속 세균 유래 나노소포 및 이의 용도 | |
KR102194274B1 (ko) | 카테니박테리움 속 세균 유래 나노소포 및 이의 용도 | |
WO2019168330A1 (fr) | Nanovésicules dérivées de bactéries streptococcus sp., et leur utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19738195 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020538572 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019738195 Country of ref document: EP Effective date: 20200812 |